...
首页> 外文期刊>European review for medical and pharmacological sciences. >Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis
【24h】

Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis

机译:长期非编码RNA UCA1通过调节MIR-654-5P / SIK2轴来促进卵巢癌中紫杉醇抗性的进展

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Ovarian cancer (OC) is a common tumor in women, and the development of chemoresistance is the major obstacle to its treatment. Long non-coding RNAs (LncRNAs) have been linked to chemoresistance in many cancers. However, the function of lncRNA urothelial carcinoma associated1 (UCA1) in paclitaxel (PTX) resistance of OC is not well elucidated. PATIENTS AND METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of UCA1, microRNA-654-5p (miR-654-5p) and salt inducible kinase 2 (SIK2). Cell PTX resistance and proliferation were evaluated by 3-(4, 5-dimethyl-2 thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The abilities of apoptosis, migration and invasion were measured by Flow cytometry and Transwell assays, respectively. Dual-luciferase reporter assay was used to verify the interaction among UCA1, miR-654-5p and SIK2. Besides, Western blot analysis was performed to assess the protein level of SIK2. RESULTS: UCA1 was markedly upregulated in OC tissues and PTX-resistant OC cells. Silencing of UCA1 restrained the PTX resistance, reduced the proliferation, migration, invasion and enhanced the apoptosis of PTX-resistant OC cells. MiR-654-5p could be sponged by UCA1, and the inhibitory effect of its overexpression on the progression of PTX-resistant OC cells could be reversed by overexpressed-UCA1. Moreover, SIK2 was a target of miR-654-5p. Silencing of SIK2 could hinder the PTX resistance and suppress the progression of PTX-resistant OC cells, while miR-654-5p inhibitor could invert this inhibitory effect. Also, the expression of SIK2 was regulated by miR-654-5p and UCA1 expression. CONCLUSIONS: LncRNA UCA1 plays an active role in PTX resistance of OC and is crucial to maintain the development of PTX resistance in OC, which provides a new therapeutic target for the study of OC chemoresistance.
机译:目的:卵巢癌(OC)是女性常见的肿瘤,化学抑制的发展是其治疗的主要障碍。长期非编码RNA(LNCRNA)与许多癌症中的化学抑制有关。然而,OC的紫杉醇(PTX)抗性的LNCRNA尿路上皮癌的功能并不迅速。患者和方法:使用定量实时聚合酶链反应(QRT-PCR)检测UCA1,MicroRNA-654-5P(miR-654-5P)和盐诱导激酶2(Sik2)的表达。通过3-(4,5-二甲基-2噻唑基)-2,5-二苯基-2- H-四唑溴铵(MTT)测定评价细胞PTX抗性和增殖。通过流式细胞术和Transwell测定法测量凋亡,迁移和侵袭的能力。双荧光素酶报告器测定用于验证UCA1,miR-654-5p和Sik2之间的相互作用。此外,进行蛋白质印迹分析以评估Sik2的蛋白质水平。结果:UCA1在OC组织和PTX抗性OC细胞中显着上调。 UCA1的沉默抑制了PTX抗性,降低了增殖,迁移,侵袭,增强了PTX抗性OC细胞的凋亡。 miR-654-5p可以由UCA1海绵,并且其过表达对PTX抗性OC细胞进展的抑制作用可以通过过表达-UCA1反转。此外,Sik2是miR-654-5p的目标。 Sik2的沉默可能阻碍PTX抗性并抑制PTX抗性OC细胞的进展,而MiR-654-5P抑制剂可以反转这种抑制作用。此外,Sik2的表达由MiR-654-5P和UCA1表达调节。结论:LNCRNA UCA1在OC的PTX抗性中发挥活跃作用,至关重要,以维持OC的PTX抗性的发展,为OC ChemoTationistance进行了新的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号